Find a Clinical Trial

Showing 31 - 40 of 229 Trials

A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone To Improve Persistence With Endocrine Therapy In Young Women With Stage I-III Breast Cancer (ASPEN)

Principal Investigator:

Claire Marie Sathe, MD

Contact Number:

212-342-5162

NCT Number:

NCT05568472

Population:

Adult

Phase:

III

This study is being done to answer the following question: Will monitoring side effects in between clinic visits help women keep taking their hormone therapy medicine as prescribed for early-stage breast cancer? This study is being done to find out if this approach is better or worse than the usual approach for helping women take their hormone therapy medicine. The usual approach is the follow-up care most people get after they are diagnosed with breast cancer and start hormone therapy. Are you Eligible? (Inclusion Criteria) Are you 18 years of age or older, but not yet menopausal? Have you...
A Randomized Phase III Trial of Intravesical BCG veRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Naïve High-Grade Non-Muscle Invasive Bladder Cancer (BRIDGE)

Principal Investigator:

Andrew T Lenis, MD

Contact Number:

212-342-5162

Population:

Adult

Phase:

III

This study is being done to answer the following question: Can we lower the chance of your bladder cancer growing or spreading by using one type of chemotherapy instilled in the bladder, Gemcitabine and Docetaxel, instead of the usual therapy? The usual approach for patients who are not in a study is treatment with Transurethral surgery of bladder tumor (TURBT) followed by instillations of Bacillus Calmette-Guerin (BCG) immunotherapy into the bladder via a catheter. We are doing this study because we want to find out if this approach is better or worse than the usual approach for your bladder...
ALKS 4230-007/GOG-3063/ENGOT-ov68: A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator’s Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian

Principal Investigator:

June Y. Hou, MD

Contact Number:

212-342-5162

NCT Number:

NCT05092360

Population:

Adult

Phase:

III

The purpose of this study is to find answers to the following research questions: • How effective is nemvaleukin alone and in combination with Pembrolizumab in treating your epithelial ovarian, fallopian tube, or primary peritoneal cancer compared with chemotherapy? • What effect does nemvaleukin alone and in combination with Pembrolizumab have on your body and epithelial ovarian, fallopian tube, or primary peritoneal cancer? • What effect does nemvaleukin in combination with Pembrolizumab have on your overall health and well-being? • How does nemvaleukin in combination...
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis

Principal Investigator:

Rajshekar Chakraborty, MD

Contact Number:

212-342-5162

NCT Number:

NCT04973137

Population:

Adult

Phase:

III

The purpose of this study is to evaluate whether birtamimab plus standard of care will improve survival in subjects with Mayo Stage IV AL amyloidosis. Birtamimab has not yet been approved by the Food and Drug Administration (FDA). During the first phase of the study, the purpose of this study is to evaluate whether birtamimab plus standard of care will improve survival in subjects with Mayo Stage IV AL amyloidosis. For the first phase of the study where neither the researchers nor the study subjects know who is getting the experimental treatment and who is getting a placebo (the double-blind...
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING ATEZOLIZUMAB AND BEVACIZUMAB, WITH OR WITHOUT TIRAGOLUMAB, IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA

Principal Investigator:

Linda Y. Wu, MD

Contact Number:

212-342-5162

NCT Number:

NCT05904886

Population:

Adult

Phase:

III

The purpose of this study is to compare the effects, good or bad, of tiragolumab plus atezolizumab plus bevacizumab versus placebo plus atezolizumab plus bevacizumab on patients with HCC. In this study, participants will be randomized you will get either tiragolumab plus atezolizumab plus bevacizumab or placebo plus atezolizumab plus bevacizumab. A placebo looks like a drug but has no active ingredient.Tiragolumab has not been approved by FDA to treat HCC. Atezolizumab plus bevacizumab is currently the standard of care. Are you Eligible? (Inclusion Criteria) Age 18 years or older at the time...
ANBL1232: Utilizing Response and Biology Risk Factors to guide Therapy in Patients with Non-Risks Neuroblastoma

Principal Investigator:

Nobuko Hijiya, MD

Contact Number:

212-342-5162

NCT Number:

NCT02176967

Population:

Pediatrics

Phase:

III

This phase III study is looking at whether using certain risk factors and biomarkers (proteins and/or gene changes in tumor cells) to determine how much treatment a younger patient with non-high risk neuroblastoma should receive will allow for a decrease in treatment for these patients while still curing their neuroblastoma. For some patients, this may include no treatment and only close observation. Measuring biomarkers in tumor cells may help plan when effective treatment is necessary and what the best treatment is. This may help to avoid some of the risks and side effects related to...
AAML1831: A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations

Principal Investigator:

Nobuko Hijiya, MD

Contact Number:

212-342-5162

NCT Number:

NCT04293562

Population:

Pediatrics

Phase:

III

This is a Phase 3 trial that will compare the efficacy of CPX-351 (a combination of 2 standard chemotherapy medicines - Daunorubicin and Cytarabine) compared to standard chemotherapy in the treatment of Acute Myelogenous Leukemia (AML). Patients will be randomly assigned by a computer to receive treatment with either CPX-351 treatment regimen or the standard chemotherapy regimen. In addition, if testing shows that a patient's AML has a specific gene change (FLT3), then those patients will be offered treatment with a new medicine (Gilteritinib) that targets the FLT3 gene change. For all...
A Phase 3 Randomized, Open-Label, Multicenter StudyEvaluating the Efficacy of Axicabtagene Ciloleucel VersusStandard of Care Therapy in Subjects withRelapsed/Refractory Follicular Lymphoma

Principal Investigator:

Ran Reshef, MD, MSc

Contact Number:

212-342-5162

NCT Number:

NCT05371093

Population:

Adult

Phase:

III

You are being invited to take part in a research study that includes studying an experimental treatment named axicabtagene ciloleucel, referred to as “axi-cel”. The experimental treatment would involve removing some of your immune cells, genetically engineering those cells to identify cancer, receiving additional therapy while you wait for those cells to be released, and then infusing those cells back and assessing the effect on your cancer cells. The purpose of this main study is to determine if the experimental treatment, axi-cel, is safe and effective in treating your relapsed...
BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to determine the Preventive Effect of Denosumab on Breast Cancer in Women carrying a BRCA1 Germline Mutation

Principal Investigator:

Katherine D Crew, MD

Contact Number:

212-342-5162

NCT Number:

NCT04711109

Population:

Adult

Phase:

III

The purpose of this study is to find out whether denosumab can decrease or prevent the risk of developing breast cancer in women carrying the BRCA1 mutation, looking at whether denosumab can decrease the risk of developing ovarian cancer or other types of cancer in women carrying the BRCA1 mutation, and studying the drug’s safety and its effect on bone health. The study team also will be monitoring for any potential side effects the drug might cause. Are you Eligible? (Inclusion Criteria) Are you between the ages of 25 and 55? Have doctors found that you have a mutation in the BRCA1...
Double-blind, randomized, placebo-controlled, prospective Phase III study evaluating efficacy and safety of Panzyga in Primary Infection Prophylaxis in patients with Chronic Lymphocytic Leukemia (“PRO-SID” study)

Principal Investigator:

Nicole Lamanna, MD

Contact Number:

212-342-5162

NCT Number:

NCT04502030

Population:

Adult

Phase:

III

This study will be performed to determine if Panzyga (the study drug) can help with preventing infections in patients who have chronic lymphocytic leukemia (CLL). The immune system is a bodily system that protects the body from foreign substances, infection agents, cells, and tissues. When the immune system does not work properly, it´s called immunodeficiency. This can be caused by hematological malignancies (forms of cancer that begin in the cells of blood-forming tissue, such as the bone marrow, or in the cells of the immune system) like chronic lymphocytic leukemia (CLL). That´...

Find a Clinical Trial

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Pages